Last10K.com

Ascendis Pharma As (ASND) SEC Filing 6-K Foreign Issuer Report for the period ending Thursday, March 31, 2022

Ascendis Pharma As

HISTORY TOOLS
CIK: 1612042 Ticker: ASND

View differences made from one to another to evaluate Ascendis Pharma As's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 6-K Foreign Issuer Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Ascendis Pharma As.

Continue

Assess how Ascendis Pharma As's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Ascendis Pharma As's Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

Tools

Financial Statements, Disclosures and Schedules

Inside this 6-K Foreign Issuer Report

Cover Page
Consolidated Cash Flow Statements
Consolidated Statements Of Changes In Equity
Consolidated Statements Of Financial Position
Consolidated Statements Of Profit Or Loss And Other Comprehensive Income
Consolidated Statements Of Profit Or Loss And Other Comprehensive Income (Parenthetical)
Financial Assets And Financial Liabilities
Financial Assets And Financial Liabilities (Tables)
Financial Assets And Financial Liabilities - Additional Information (Detail)
Financial Assets And Financial Liabilities - Liquidity Risk Management (Detail)
Financial Assets And Financial Liabilities - Schedule Of Financial Assets And Liabilities (Detail)
Financial Assets And Financial Liabilities - Summary Of Marketable Securities (Detail)
General Information
Revenue
Revenue (Tables)
Revenue - Additional Information (Detail)
Revenue - Schedule Of Revenue Recognized In Consolidated Statements Of Profit Or Loss (Detail)
Revenue - Schedule Of Revenue Recognized In Consolidated Statements Of Profit Or Loss (Parenthetical) (Detail)
Segment Information
Segment Information - Additional Information (Detail)
Share Capital
Share Capital - Additional Information (Detail)
Share-Based Payment
Share-Based Payment (Tables)
Share-Based Payment - Additional Information (Details)
Share-Based Payment - Schedule Of Warrant Activity (Detail)
Share-Based Payment - Summary Of Share Based Payment (Detail)
Significant Accounting Judgements And Estimates
Significant Events In The Reporting Period
Significant Events In The Reporting Period - Additional Information (Detail)
Subsequent Events
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (Policies)
Summary Of Significant Accounting Policies - Additional Information (Detail)
Treasury Shares
Treasury Shares (Tables)
Treasury Shares - Summary Of Holding Of Treasury Shares (Detail)

Material Contracts, Statements, Certifications & more

Ascendis Pharma As provided additional information to their SEC Filing as exhibits

Exhibit 99.1: Additional Exhibits
Exhibit 99.2: Additional Exhibits
Ticker: ASND
CIK: 1612042
Form Type: 6-K Foreign Issuer Report
Accession Number: 0001193125-22-147494
Submitted to the SEC: Wed May 11 2022 4:06:19 PM EST
Accepted by the SEC: Wed May 11 2022
Period: Thursday, March 31, 2022
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/asnd/0001193125-22-147494.htm